Introduction Immune checkpoint inhibitors (ICIs) are increasingly used to treat cancers.
Kidney immune-related adverse events (IRAEs) are now well recognized, with the incidence …

Abstract Rationale & Objective The approved therapeutic indication for immune checkpoint
inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the …

Since their introduction into clinical practice a decade ago, immune checkpoint inhibitors
(ICIs) have had an overwhelming impact on cancer treatment. Use of these agents in …

Introduction Immune checkpoint inhibitors (ICIs) are effective in treating several cancers;
however, acute kidney injury (AKI) can occur as part as an immune-related adverse event …

Background The objective of this case cohort study was to describe our experience in the
care of patients with immune checkpoint inhibitor–related acute interstitial nephritis (ICI-AIN) …

Renal toxicities have been increasingly recognized as complications of the immune
checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk …

Background Immune checkpoint inhibitors (ICPi) are a novel and promising anti-cancer
therapy. There are limited data on the incidence, risk factors and outcomes of acute kidney …

Immune checkpoint inhibitors (ICPIs) have transformed the landscape of oncology, but are
associated with a variety of autoimmune adverse events, including AKI. ICPI-associated AKI …

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies directed at negative
regulatory components on T cells, such as cytotoxic T lymphocyte‐associated antigen 4 …

Abstract Background/objectives Acute Kidney Injury (AKI), induced by Checkpoint Inhibitors
therapies (CPI-induced AKI), is an uncommon but severe Immune-Related Adverse Event …